BMP-9 induced osteogenic differentiation of mesenchymal stem cells: Molecular mechanism and therapeutic potential

Current Gene Therapy

Volumn 11, Issue 3, 2011, Pages 229-240

  Luther, Gaurav ^a   Wagner, Eric R ^a   Zhu, Gaohui ^a,b   Kang, Quan ^a,b   Luo, Qing ^a,b   Lamplot, Joseph ^a   Bi, Yang ^a   Luo, Xiaoji ^a,c   Luo, Jinyong ^a,c   Teven, Chad ^a   Shi, Qiong ^a,c   Kim, Stephanie H ^a   Gao, Jian Li ^a,d   Huang, Enyi ^a,e   Yang, Ke ^a,f   Rames, Richard ^a   Liu, Xing ^a,b   Li, Mi ^a,b   Hu, Ning ^a,c   Liu, Hong ^a,c   Su, Yuxi ^a,b   Chen, Liang ^a,c   He, Bai Cheng ^a,c   Zuo, Guo Wei ^a,c   Deng, Zhong Liang ^a,c   Reid, Russell R ^a   Luu, Hue H ^a   Haydon, Rex C ^a   He, Tong Chuan ^a,b,c   more..

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^e CHONGQING UNIVERSITY   (China)

^f THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

BMP 9; Bone formation; Bone regeneration; Cell based gene therapy; Fracture healing; GDF 2; Mesenchymal stem cells

Indexed keywords

ADENOVIRUS BONE MORPHOGENETIC PROTEIN 9 VECTOR; ADENOVIRUS VECTOR; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 10; BONE MORPHOGENETIC PROTEIN 11; BONE MORPHOGENETIC PROTEIN 12; BONE MORPHOGENETIC PROTEIN 14; BONE MORPHOGENETIC PROTEIN 15; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEIN 8; BONE MORPHOGENETIC PROTEIN 9; BONE MORPHOGENETIC PROTEIN 9 PLASMID VECTOR; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH DIFFERENTIATION FACTOR 6; OSTEOGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMID VECTOR; RETINOIC ACID; SMAD PROTEIN; SOMATOMEDIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTERIOR SPINE FUSION; ARTICLE; BONE REGENERATION; CLINICAL EFFECTIVENESS; DNA BINDING; ENCHONDRAL OSSIFICATION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 79958202199     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652311795684777     Document Type: Article

References (162)

1. Luo J, Sun MH, Kang Q, et al. Gene therapy for bone regeneration. Curr Gene Ther 2005 Apr;5(2):167-179.
2. Chen L, Jiang W, Huang J, et al. Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res 2010;25:2447-2459.
3. Cherry DK, Woodwell DA. National Ambulatory Medical Care Survey: 2000 summary. Adv Data 2002; 5:1-32.
4. Kang Q, Sun MH, Cheng H, et al. Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery. Gene Ther 2004;11:1312-1320.
5. Einhorn TA, Lee CA. Bone regeneration: new findings and potential clinical applications. J Am Acad Orthop Surg 2001;9:157-165.
6. Dickson K, Katzman S, Delgado E, Contreras D. Delayed unions and nonunions of open tibial fractures. Correlation with arteriography results. Clin Orthop Relat Res 1994:189-193.
7. Kwiatkowski TC, Hanley EN, Jr., Ramp WK. Cigarette smoking and its orthopedic consequences. Am J Orthop (Belle Mead NJ) 1996;25:590-597.
8. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
9. Sarmiento A. On the behavior of closed tibial fractures: clinical/radiological correlations. J Orthop Trauma 2000;14:199-205.
10. Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001;286:2815-2822.
11. Boden SD. Overview of the biology of lumbar spine fusion and principles for selecting a bone graft substitute. Spine (Phila Pa 1976) 2002;27:S26-S31.
12. Heckman JD, Boyan BD, Aufdemorte TB, Abbott JT. The use of bone morphogenetic protein in the treatment of non-union in a canine model. J Bone Joint Surg Am 1991;73:750-764.
13. Gerhart TN, Kirker-Head CA, Kriz MJ, et al. Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. Clin Orthop Relat Res 1993:317-326.
14. Lee SC, Shea M, Battle MA, et al. Healing of large segmental defects in rat femurs is aided by RhBMP-2 in PLGA matrix. J Biomed Mater Res 1994 Oct;28(10):1149-1156.
15. Bostrom MP, Camacho NP. Potential role of bone morphogenetic proteins in fracture healing. Clin Orthop Relat Res 1998:S274-S282.
16. Cheng SL, Lou J, Wright NM, Lai CF, Avioli LV, Riew KD. In vitro and in vivo induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene. Calcif Tissue Int 2001;68:87-94.
17. Krebsbach PH, Gu K, Franceschi RT, Rutherford RB. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 2000;11:1201-1210.
18. Partridge K, Yang X, Clarke NM, et al. Adenoviral BMP-2 gene transfer in mesenchymal stem cells: in vitro and in vivo bone formation on biodegradable polymer scaffolds. Biochem Biophys Res Commun 2002;292:144-152.
19. Riew KD, Wright NM, Cheng S, Avioli LV, Lou J. Induction of bone formation using a recombinant adenoviral vector carrying the human BMP-2 gene in a rabbit spinal fusion model. Calcif Tissue Int 1998;63:357-360.
20. Varady P, Li JZ, Alden TD, Kallmes DF, Williams MB, Helm GA. CT and radionuclide study of BMP-2 gene therapy-induced bone formation. Acad Radiol 2002;9:632-637.
21. Varady P, Li JZ, Cunningham M, et al. Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 2001;12:697-710.
22. Helm GA, Alden TD, Beres EJ, et al. Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent. J Neurosurg 2000;92:191-196.
23. Sandhu HS, Khan SN, Suh DY, Boden SD. Demineralized bone matrix, bone morphogenetic proteins, and animal models of spine fusion: an overview. Eur Spine J 2001;10:S122-S131.
24. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 2000;25:376-381.
25. Friedlaender GE. OP-1 clinical studies. J Bone Joint Surg Am 2001;83:S160-S161.
26. Olsen BR, Reginato AM, Wang W. Bone development. Annu Rev Cell Dev Biol 2000;16:191-220.
27. Ducy P, Karsenty G. The family of bone morphogenetic proteins. Kidney Int 2000;57:2207-2214.
28. Ducy P, Starbuck M, Priemel M, et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 1999;13:1025-1036.
29. Reddi AH. Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat Biotechnol 1998;16:247-252.
30. Urist MR. Bone: formation by autoinduction. Science 1965;150:893-899.
31. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988;242:1528-1534.
32. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003;113:685-700.
33. Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily. Science 2002;296:1646-1647.
34. Varga AC, Wrana JL. The disparate role of BMP in stem cell biology. Oncogene 2005;24:5713-5721.
35. Zhang J, Li L. BMP signaling and stem cell regulation. Dev Biol 2005;284:1-11.
36. Luu HH, Song WX, Luo X, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. J Orthop Res 2007;25:665-677.
37. Derynck R, Feng XH. TGF-beta receptor signaling. Biochim Biophys Acta 1997;1333:F105-F150.
38. Christiansen JH, Coles EG, Wilkinson DG. Molecular control of neural crest formation, migration and differentiation. Current opinion in cell biology 2000;12:719-724.
39. Hu J, Chen YX, Wang D, et al. Developmental expression and function of Bmp4 in spermatogenesis and in maintaining epididymal integrity. Developmental biology 2004;276:158-171.
40. Mitu G, Hirschberg R. Bone morphogenetic protein-7 (BMP7) in chronic kidney disease. Frontiers in bioscience: a journal and virtual library 2008;13:4726-4739.
41. Di Cesare PE, Frenkel SR, Carlson CS, Fang C, Liu C. Regional gene therapy for full-thickness articular cartilage lesions using naked DNA with a collagen matrix. Journal of orthopaedic research: official publication of the Orthopaedic Research Society 2006;24:1118-1127.
42. Kuo AC, Rodrigo JJ, Reddi AH, Curtiss S, Grotkopp E, Chiu M. Microfracture and bone morphogenetic protein 7 (BMP-7) synergistically stimulate articular cartilage repair. Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2006;14:1126-1135.
43. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev 1996;10:1580-1594.
44. Zhao GQ. Consequences of knocking out BMP signaling in the mouse. Genesis 2003;35:43-56.
45. Massague J, Weis-Garcia F. Serine/threonine kinase receptors: mediators of transforming growth factor beta family signals. Cancer Surv 1996;27:41-64.
46. Yamashita H, Ten Dijke P, Heldin CH, Miyazono K. Bone morphogenetic protein receptors. Bone 1996;19:569-574.
47. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
48. Massague J. TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
49. Wrana JL. Regulation of Smad activity. Cell 2000;100:189-192.
50. Whang K, Tsai DC, Nam EK, et al. Ectopic bone formation via rhBMP-2 delivery from porous bioabsorbable polymer scaffolds. J Biomed Mater Res 1998;42:491-499.
51. Alden TD, Pittman DD, Beres EJ, et al. Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapy. J Neurosurg 1999;90:109-114.
52. Oyama M, Tatlock A, Fukuta S, et al. Retrovirally transduced bone marrow stromal cells isolated from a mouse model of human osteogenesis imperfecta (oim) persist in bone and retain the ability to form cartilage and bone after extended passaging. Gene Ther 1999;6:321-329.
53. Alden TD, Pittman DD, Hankins GR, et al. In vivo endochondral bone formation using a bone morphogenetic protein 2 adenoviral vector. Hum Gene Ther 1999;10:2245-2253.
54. Baltzer AW, Lattermann C, Whalen JD, et al. Genetic enhancement of fracture repair: healing of an experimental segmental defect by adenoviral transfer of the BMP-2 gene. Gene Ther 2000;7:734-739.
55. Baltzer AW, Lattermann C, Whalen JD, et al. Potential role of direct adenoviral gene transfer in enhancing fracture repair. Clin Orthop Relat Res 2000:S120-S125.
56. Bosch P, Musgrave D, Ghivizzani S, Latterman C, Day CS, Huard J. The efficiency of muscle-derived cell-mediated bone formation. Cell Transplant 2000;9:463-470.
57. Breitbart AS, Grande DA, Mason JM, Barcia M, James T, Grant RT. Gene-enhanced tissue engineering: applications for bone healing using cultured periosteal cells transduced retrovirally with the BMP-7 gene. Ann Plast Surg 1999;42:488-495.
58. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000;78:476-486.
59. Gazit D, Turgeman G, Kelley P, et al. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: a novel cell-mediated gene therapy. J Gene Med 1999;1:121-133.
60. Lieberman JR, Le LQ, Wu L, et al. Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998;16:330-339.
61. Lou J, Xu F, Merkel K, Manske P. Gene therapy: adenovirusmediated human bone morphogenetic protein-2 gene transfer induces mesenchymal progenitor cell proliferation and differentiation in vitro and bone formation in vivo. J Orthop Res 1999;17:43-50.
62. Mason JM, Grande DA, Barcia M, Grant R, Pergolizzi RG, Breitbart AS. Expression of human bone morphogenic protein 7 in primary rabbit periosteal cells: potential utility in gene therapy for osteochondral repair. Gene Ther 1998;5:1098-1104.
63. Musgrave DS, Bosch P, Ghivizzani S, Robbins PD, Evans CH, Huard J. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 1999;24:541-547.
64. Okubo Y, Bessho K, Fujimura K, Iizuka T, Miyatake SI. Osteoinduction by bone morphogenetic protein-2 via adenoviral vector under transient immunosuppression. Biochem Biophys Res Commun 2000;267:382-387.
65. Ripamonti U, Ramoshebi LN, Matsaba T, Tasker J, Crooks J, Teare J. Bone induction by BMPs/OPs and related family members in primates. J Bone Joint Surg Am 2001;83:S116-S127.
66. Lee JY, Musgrave D, Pelinkovic D, et al. Effect of bone morphogenetic protein-2-expressing muscle-derived cells on healing of critical-sized bone defects in mice. J Bone Joint Surg Am 2001;83:1032-1039.
67. Govender S, Csimma C, Genant HK, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002;84:2123-2134.
68. Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine (Phila Pa 1976) 2002;27:2654-2661.
69. Cook SD, Salkeld SL, Brinker MR, Wolfe MW, Rueger DC. Use of an osteoinductive biomaterial (rhOP-1) in healing large segmental bone defects. J Orthop Trauma 1998;12:407-412.
70. Cook SD, Baffes GC, Wolfe MW, Sampath TK, Rueger DC, Whitecloud TS, 3rd. The effect of recombinant human osteogenic protein-1 on healing of large segmental bone defects. J Bone Joint Surg Am 1994;76:827-838.
71. Kang Q, Song WX, Luo Q, et al. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 2009;18:545-559.
72. Song JJ, Celeste AJ, Kong FM, Jirtle RL, Rosen V, Thies RS. Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation. Endocrinology 1995;136:4293-4297.
73. Lopez-Coviella I, Berse B, Krauss R, Thies RS, Blusztajn JK. Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science 2000;289:313-316.
74. Chen C, Grzegorzewski KJ, Barash S, et al. An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat Biotechnol 2003;21:294-301.
75. Truksa J, Peng H, Lee P, Beutler E. Bone morphogenetic proteins 2, 4, and 9 stimulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2 (Tfr2), and IL-6. Proc Natl Acad Sci USA 2006;103:10289-10293.
76. Luo J, Tang M, Huang J, et al. TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem 2010;285:29588-29598.
77. Cheng H, Jiang W, Phillips FM, et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 2003;85:1544-1552.
78. Peng Y, Kang Q, Cheng H, et al. Transcriptional characterization of bone morphogenetic proteins (BMPs)-mediated osteogenic signaling. J Cell Biochem 2003;90:1149-1165.
79. Peng Y, Kang Q, Luo Q, et al. Inhibitor of DNA binding/differentiation helix-loop-helix proteins mediate bone morphogenetic protein-induced osteoblast differentiation of mesenchymal stem cells. J Biol Chem 2004;279:32941-32949.
80. Luo Q, Kang Q, Si W, et al. Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 2004;279:55958-55968.
81. Si W, Kang Q, Luu HH, et al. CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3Ainduced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 2006;26:2955-2964.
82. Brown MA, Zhao Q, Baker KA, et al. Crystal structure of BMP-9 and functional interactions with pro-region and receptors. J Biol Chem 2005;280:25111-25118.
83. Sieber C, Kopf J, Hiepen C, Knaus P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009;20:343-355.
84. Hill JJ, Qiu Y, Hewick RM, Wolfman NM. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol 2003;17:1144-1154.
85. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003;24:218-235.
86. Li JZ, Li H, Sasaki T, et al. Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat. Gene Ther 2003;10:1735-1743.
87. Zhou L, An N, Jiang W, et al. Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. Biotechniques 2002 Nov;33(5):1126-1128, 30, 32 passim.
88. He BC, Chen L, Zuo GW, et al. Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 2010;16:2235-2245.
89. Aubin JE. Regulation of osteoblast formation and function. Rev Endocr Metab Disord 2001;2:81-94.
90. Deng ZL, Sharff KA, Tang N, et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci 2008;13:2001-2021.
91. Wagner ER, He BC, Chen L, et al. Therapeutic Implications of PPARgamma in Human Osteosarcoma. PPAR Res 2010;2010:956427.
92. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008;466:2114-2130.
93. He TC. Distinct osteogenic activity of BMPs and their orthopaedic applications. J Musculoskelet Neuronal Interact 2005;5:363-366.
94. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000;21:393-411.
95. Lian JB, Stein GS, Javed A, et al. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord 2006;7:1-16.
96. Karsenty G. Role of Cbfa1 in osteoblast differentiation and function. Semin Cell Dev Biol 2000;11:343-346.
97. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 2006;99:1233-1239.
98. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-764.
99. Inada M, Yasui T, Nomura S, et al. Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn 1999;214:279-290.
100. Bergwitz C, Wendlandt T, Kispert A, Brabant G. Wnts differentially regulate colony growth and differentiation of chondrogenic rat calvaria cells. Biochim Biophys Acta 2001;1538:129-140.
101. Fischer L, Boland G, Tuan RS. Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. J Cell Biochem 2002;84:816-831.
102. Wang J, Wynshaw-Boris A. The canonical Wnt pathway in early mammalian embryogenesis and stem cell maintenance/differentiation. Curr Opin Genet Dev 2004;14:533-539.
103. Gregory CA, Gunn WG, Reyes E, et al. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann N Y Acad Sci 2005;1049:97-106.
104. Gavin BJ, McMahon JA, McMahon AP. Expression of multiple novel Wnt-1/int-1-related genes during fetal and adult mouse development. Genes Dev 1990;4:2319-2332.
105. Kengaku M, Capdevila J, Rodriguez-Esteban C, et al. Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud. Science 1998;280:1274-1277.
106. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006;116:1202-1209.
107. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494.
108. Haydon RC, Deyrup A, Ishikawa A, et al. Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 2002;102:338-342.
109. Glass DA, 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007;148:2630-2634.
110. Luo J, Chen J, Deng ZL, et al. Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 2007;87:97-103.
111. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005;434:843-850.
112. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
113. Haydon RC, Luu HH, He TC. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007;454:237-246.
114. Luo X, Chen J, Song WX, et al. Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 2008;88:1264-1277.
115. Santos JL, Pandita D, Rodrigues J, Pego AP, Granja PL, Tomas H. Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration. Curr Gene Ther 2011;11:46-57.
116. Sheyn D, Kimelman-Bleich N, Pelled G, Zilberman Y, Gazit D, Gazit Z. Ultrasound-based nonviral gene delivery induces bone formation in vivo. Gene Ther 2008;15:257-266.
117. Aslan H, Zilberman Y, Arbeli V, et al. Nucleofection-based ex vivo nonviral gene delivery to human stem cells as a platform for tissue regeneration. Tissue Eng 2006;12:877-889.
118. Bergeron E, Senta H, Mailloux A, Park H, Lord E, Faucheux N. Murine preosteoblast differentiation induced by a peptide derived from bone morphogenetic proteins-9. Tissue Eng Part A 2009 Nov;15(11):3341-3349.
119. Lee JY, Peng H, Usas A, et al. Enhancement of bone healing based on ex vivo gene therapy using human muscle-derived cells expressing bone morphogenetic protein 2. Hum Gene Ther 2002;13:1201-1211.
120. Li JZ, Hankins GR, Kao C, Li H, Kammauff J, Helm GA. Osteogenesis in rats induced by a novel recombinant helperdependent bone morphogenetic protein-9 (BMP-9) adenovirus. J Gene Med 2003;5:748-756.
121. Dumont RJ, Dayoub H, Li JZ, et al. Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents. Neurosurgery 2002 Nov;51(5):1239-1244; discussion 44-45.
122. Kimelman-Bleich N, Pelled G, Zilberman Y, et al. Targeted geneand-host progenitor cell therapy for nonunion bone fracture repair. Mol Ther 2011;19:53-59.
123. Yamashita H, Miyazono K. [Bone morphogenetic protein (BMP) receptors and signal transduction]. Nippon Rinsho 1999;57:220-226.
124. Scharpfenecker M, van Dinther M, Liu Z, et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J Cell Sci 2007;120:964-972.
125. Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem 2009;284:15794-15804.
126. Shao ES, Lin L, Yao Y, Bostrom KI. Expression of vascular endothelial growth factor is coordinately regulated by the activinlike kinase receptors 1 and 5 in endothelial cells. Blood 2009;114):2197-2206.
127. Wu N, Zhao Y, Yin Y, Zhang Y, Luo J. Identification and analysis of type II TGF-{beta} receptors in BMP-9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai) 2010;42:699-708.
128. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000;113:3897-3905.
129. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol 2003;13:410-418.
130. Kreider BL, Benezra R, Rovera G, Kadesch T. Inhibition of myeloid differentiation by the helix-loop-helix protein Id. Science 1992;255:1700-1702.
131. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999;248:44-57.
132. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000;71:276-292.
133. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 2002;21:473-482.
134. Brigstock DR. The CCN family: a new stimulus package. J Endocrinol 2003;178:169-175.
135. Brigstock DR, Goldschmeding R, Katsube KI, et al. Proposal for a unified CCN nomenclature. Mol Pathol 2003;56:127-128.
136. Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003;3:15.
137. Ivkovic S, Yoon BS, Popoff SN, et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003;130:2779-2791.
138. Kennedy L, Liu S, Shi-Wen X, et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp Cell Res 2007;313:952-964.
139. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002 Nov;14(6):681-685.
140. Zuo GW, Kohls CD, He BC, et al. The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis. Histol Histopathol 2010;25:795-806.
141. Sharff KA, Song WX, Luo X, et al. Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 2009;284:649-659.
142. Tang N, Song WX, Luo J, et al. BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 2009;13:2448-2464.
143. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
144. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-3305.
145. Glass DA, 2nd, Karsenty G. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway. Curr Top Dev Biol 2006;73:43-84.
146. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513-523.
147. Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam Clin Pharmacol 2007;21:231-244.
148. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009;66:236-253.
149. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
150. Yu K, Bayona W, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995;270:23975-23983.
151. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
152. Rosen ED, Sarraf P, Troy AE, et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell1999;4:611-617.
153. Barak Y, Nelson MC, Ong ES, et al. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999;4:585-595.
154. Beamer BA, Yen CJ, Andersen RE, et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptorgamma2 gene with obesity in two Caucasian populations. Diabetes 1998;47:1806-1808.
155. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-287.
156. Zhang W, Deng ZL, Chen L, et al. Retinoic acids potentiate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS One 2010;5:e11917.
157. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005;86:84-90.
158. O'Dell SD, Day IN. Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998;30:767-771.
159. Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008;134:921-931.
160. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008;9:541-553.
161. Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 2006;46:451-480.
162. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001;294:1866-1870.